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Poisons and medicine are oftentimes the same substance given with 
different intents. 
Peter Mere Latham 
Because coronary artery disease is the most frequent cause 
of left ventricular dysfunction in the United States and 
Europe, it is common to see patients with heart failure who 
complain of angina pectoris either at rest or on exertion. 
Anginal symptoms may be mild and add little to exercise 
intolerance, or they may be severe and emerge as the 
primary reason for the patient's disability. Physicians have 
long assumed that when cardiac failure and cardiac ischemia 
coexist, the two conditions should be managed indepen-
dently: each disease should be treated as if the other were 
not present. This approach has been strongly supported by 
the beliefs that 1) each condition can aggravate the other, 
and 2) most drugs used in the treatment of angina and heart 
failure share a common mechanism of action (since they all 
function to reduce ventricular size or pressure). Therefore 
we might expect that drugs used for one condition would 
help to treat the other, and thus, we see patients with both 
left ventricular dysfunction and ischemia who are receiving 
as many as seven different cardiovascular drugs: digoxin, a 
diuretic drug, a converting enzyme inhibitor, nitrates, a 
beta-adrenergic blocking agent, a calcium channel blocking 
agent and aspirin. Yet, despite such intensive medical ther-
apy, many of these patients continue to experience both 
dyspnea and angina. 
Why are these patients so difficult to treat? Certainly, we 
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have effective drugs for both heart failure and angina pecto-
ris. Controlled trials have shown that digitalis, diuretics and 
converting-enzyme inhibitors are useful in the management 
of heart failure, and that nitrates, beta-blockers, calcium 
channel blockers and aspirin are useful in the management of 
ischemic heart disease. Why then are the clinical responses 
to these drugs so disappointing when both conditions are 
present? Controlled clinical trials generally exclude patients 
who have more than one cardiovascular condition. For 
example, patients with exertional angina are not included in 
clinical trials of drugs for heart failure, and patients with 
heart failure or severe left ventricular dysfunction are ex-
cluded from controlled trials of drugs for angina pectoris. As 
a result, there is virtually no information on the efficacy and 
safety of cardiovascular drugs for one disorder when other 
conditions coexist. The dilemma is similar to the one physi-
cians face when they treat patients with heart failure who 
have serious ventricular arrhythmias. For many years, pa-
tients with heart failure were excluded from studies that 
investigated the utility and safety of antiarrhythmic agents, 
and thus, physicians treated heart failure and ventricular 
arrhythmias as if they were independent entities, since they 
had little reason to believe that drugs used in the manage-
ment of these conditions might interact unfavorably. Only 
recently have we learned that left ventricular dysfunction 
markedly decreases the efficacy and increases the toxicity of 
antiarrhythmic agents (I); the presence of heart failure 
produces a marked deleterious shift in the risk-to-benefit 
relation governing the use of these potent drugs. 
Given this experience with antiarrhythmic agents, we 
ask: does the presence of ischemia alter the response to 
drugs for heart failure? Does the presence of heart failure 
alter the efficacy and safety of antianginal agents? The study 
by Cleland et al. (2) in this issue of the Journal provides 
strong support for the occurrence of such adverse interac-
tions. 
Effect of Ischemia on Drugs for 
Heart Failure 
Digitalis. Controlled trials (3) have shown that digitalis 
improves the hemodynamic and clinical status of patients 
with chronic heart failure, whether or not they have coro-
nary artery disease. However, patients with active angina 
were never enrolled in these studies, and theoretically, such 
patients may be less responsive to and tolerant of digitalis 
than are patients without symptomatic ischemia. The symp-
toms of heart failure in patients with active angina are 
frequently related to diastolic dysfunction, which responds 
poorly to digitalis (4), possibly because digitalis exerts 
unfavorable effects on ventricular relaxation (5). Further-
more, although digitalis rarely produces serious arrhythmias 
when administered in therapeutic doses to patients with 
heart failure in stable condition, its proarrhythmic effects 
may be enhanced in the presence of active ischemia (6). 
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These experimental observations are consistent with clinical 
concerns about a possible adverse effect of digitalis on the 
survival of patients who have recovered from an acute 
myocardial infarction (7). 
Angiotensin-converting enzyme inhibitors. Angiotensin-
converting enzyme inhibitors lessen symptoms and reduce 
the risk of death in patients with chronic heart failure, 
whether or not they have coronary artery disease (3). 
Although these drugs occasionally produce marked de-
creases in systemic blood pressure (and thus, in coronary 
perfusion pressure), these hypotensive effects are rarely 
associated with end-organ ischemia, and their use in con-
trolled clinical trials has not been accompanied by reports of 
worsening angina. In fact, preliminary data (8-10) suggest 
that converting enzyme inhibitors may exert favorable ef-
fects on myocardial ischemia by dilating coronary arteries, 
reducing sympathetic stimulation of the heart and decreasing 
myocardial oxygen consumption. These physiologic actions 
may explain why converting enzyme inhibitors have been 
reported to ameliorate the development of stress-induced 
angina in patients with coronary artery disease who do not 
have heart failure (10,11). Furthermore, converting enzyme 
inhibitors have been used with increasing frequency during 
the early hours and days after an acute myocardial infarction 
to prevent the adverse hemodynamic effects of neurohor-
monal activation and ventricular dilation (12,13). 
The present study. Unfortunately, all of the controlled 
studies using converting enzyme inhibitors in patients with 
heart failure have excluded patients with active angina-at 
least until the publication in this issue of the Journal of the 
study by Cleland et al. (2). Their report presents the results 
of the first placebo-controlled study to evaluate the effects of 
a converting enzyme inhibitor (captopril) in patients with 
both angina and heart failure. In contrast to its beneficial 
effects in patients without ongoing ischemia, captopril re-
duced exercise tolerance and increased both the severity of 
angina and the consumption of nitroglycerin in patients with 
active angina. The risk of these adverse effects was directly 
related to the magnitude of the hypotensive effects of the 
drug. Angina was increased primarily in patients who expe-
rienced marked decreases in systemic blood pressure; this 
was especially true when the hypotensive effects of captopril 
and nifedipine were combined. 
Why does the presence of angina alter the risk to benefit 
relation that governs the llse of converting enzyme inhibitors 
in patients with heart failure? In patients with heart failure 
but without angina, a critical stenosis is primarily found in 
coronary arteries that supply hypocontractile (i.e., infarcted) 
myocardial segments. In the absence of viable myocardium 
distal to the stenosis, changes in coronary perfusion pressure 
in these segments may be functionally unimportant. In 
contrast, angina is a common finding if stenoses are present 
in coronary arteries that supply actively contractinR regions 
of the left ventricle, and it is likely to be exacerbated if 
coronary perfusion pressure is compromised. In the study of 
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Cleland et al. (2), this anatomic substrate was present in 
most patients who responded unfavorably to captopril. 
Effect of Heart Failure on Drugs 
for Ischemia 
Beta-adrenergic blocking drugs. Although controlled 
studies have shown that beta-blockers are potent antianginal 
agents, none of these trials enrolled patients with congestive 
heart failure, because of fears that a beta-blocker would 
aggravate heart failure. Such concerns seem reasonable, 
since any increase in cardiac size and wall stress produced 
by the negative inotropic effects of beta-blockers could act to 
limit their anti-ischemic actions. As a result, most clinicians 
have avoided the use of a beta-blocker in patients with 
coexistent heart failure and angina pectoris. However, the 
need for such caution has been recently questioned after the 
publication of the results of two long-term controlled trials 
(14,15) that showed that a beta-blocker may produce hemo-
dynamic and clinical improvement in chronic heart failure. 
Yet the benefits of beta-blockade noted in these two studies 
were observed in patients without coronary artery disease; 
patients with such disease may not respond favorably to 
these drugs (16). Any long-term benefit that beta-blockers 
may produce in patients with ischemic heart failure may be 
related primarily to their antiarrhythmic-rather than their 
anti-ischemic-effects (17). 
Calcium channel blockers. As in the case of other an-
tianginal drugs, the controlled trials that have demonstrated 
the utility of calcium channel blockers as antianginal agents 
have generally excluded patients with heart failure. In the 
few studies (18) that included such patients, patients with 
heart failure experienced the least benefit and most adverse 
reactions during treatment. Although the deleterious effects 
of calcium channel blockers in patients with left ventricular 
dysfunction have traditionally been attributed to their nega-
tive inotropic effects, recent evidence (19) has indicated that 
the hormone-stimulating actions of these drugs may underlie 
many of their detrimental effects. This hypothesis has led 
some physicians to suggest that the neurohormonal activa-
tion produced by calcium channel blockers might be reduced 
by the concomitant administration of a converting enzyme 
inhibitor. The observations of Cleland et al. (2) however, 
indicate that this combination may cause a marked hypoten-
sive reaction that can aggravate myocardial ischemia. 
Drug-Drug Interactions 
To make matters more complicated, drugs used in the 
treatment of heart failure and myocardial ischemia may 
interact with each other, both favorably and unfavorably. On 
the one hand, beta-blockers may reduce the arrhythmogenic 
potential of digitalis in subjects with ischemic heart disease 
(6). On the other hand, aspirin (which is widely used in 
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patients with angina) may attenuate the favorable hemody-
namic actions of the converting enzyme inhibitors (20). 
Therapeutic Implications 
These observations indicate that disease states may inter-
act to modify the efficacy and safety of cardiovascular drugs. 
Although much attention has recently been directed toward 
the interplay of drugs and disease in patients who have both 
heart failure and ventricular arrhythmias (I). the report by 
Cleland et al. (2) underscores the fact that similar adverse 
interactions may occur in patients who have both heart 
failure and angina pectoris. The presence of angina pectoris 
may decrease the efficacy and increase the risks of drugs for 
heart failure: the presence of heart failure may reduce the 
benefits and enhance the toxicity of antianginal agents. 
Holt' then should H'e treat patients H'ith (/ctin' symptoms 
qf' hath heart failure and angina? Although both diuretics 
and nitrates would appear to be first-line drugs in such 
individuals. many patients remain unresponsive to both 
agents. What should the clinician do when symptoms per-
sist? Controlled trials indicate that. despite a higher opera-
tive risk (21). patients with both heart failure and angina 
pectoris are ideal candidates for coronary bypass surgery. 
Revascularization offers these severely ill patients a better 
chance of survival and lessened symptoms than does phar-
macologic therapy (22). Similarly. surgery (specifically. im-
plantation of a cardiac defibrillator) may also provide an 
ideal remedy for the patient with heart failure and serious 
ventricular arrhythmias. Hence. when cardiovascular dis-
eases and cardiovascular drugs interact unfavorably. physi-
cians may accomplish more by withdrawing-rather than 
adding-drugs. Under such circumstances. mechanical ap-
proaches may provide the only therapeutic solution. 
References 
I. Pratt CM. Eaton T. Francis M. et al. The inverse relationship between 
baseline left ventricular ejection fraction and outcome of antiarrhythmic 
therapy: a dangerous imbalance in the risk-benefit ratio. Am Heart J 
1989:118:433-40. 
2. Cleland JGF. Henderson E. McLenachen J. Findlay IN. Dargie HJ. 
Effect of captopril. an angiotensin-converting enzyme inhibitor. in pa-
tients with angina pectoris and heart failure. J Am Coli Cardiol 1991: 17: 
733-9. 
3. Packer M. Vasodilator and inotropic drugs for the treatment of chronic 
heart failure: distinguishing hype from hope. J Am Coli Cardiol 1988:1:: 
1:29-317. 
4. Lee DC. Johnson RA. Bingham J B. et al. Heart failure in outpatients: a 
lACC Vol. 17. No.3 
March I. 1991 :740-2 
randomized trial of digoxin versus placebo. N Engl J Med 1982J06:699-
705. 
5. Lorell BH. Isoyama S. Grice WN. Weinberg EO. Apstein CS. Effects of 
ouabain and isoproterenol on left ventricular diastolic function during 
low-flow ischemia in isolated blood-perfused rabbit hearts. Circ Res 
1988:63:457-07. 
6. Lynch JJ. Kitzen JM. Hoff PT. Lucchesi BR. Reduction in digitalis-
associated post infarction mortality with nadolol in conscious dogs. Am 
Heart J 1988:115:07-70. 
7. Moss AJ. Davis HT. Conrad DL. DeCamilio JJ. Odoroff CL. Digitalis-
associated cardiac mortality after myocardial infarction. Circulation 1981: 
64:1150-0. 
8. Foult J-M. Tavolaro O. Anthony I. Nitenberg A. Direct myocardial and 
coronary efl'ects of enalaprilat in patients with dilated cardiomyopathy: 
assessment hy a bilateral intracoronary infusion technique. Circulation 
I 98HJ7J.'7-44. 
9. Rouleau JL. Chatterjee K. Nege W. Parmley ww. Hiramatsu B. Alter-
ations in len ventricular function and coronary hemodynamics with 
captopril. hydralazine and prazosin in chronic ischemic heart failure: a 
comparative study. Circulation 198::65:671-8. 
10. Daly P. Mettauer B. Rouleau J-L. Cousineau D. Burgess JH. Lack of 
reflex increase in myocardial sympathetic tone after captopril: potential 
antianginal effect. Circulation 1985:71:317-:5. 
II. Ikram H. Low CJS. Shirlaw T. Webb eM. Richards AM. Crozier IG. 
Antianginal. hemodynamic and coronary vascular efl'ecls of captopril in 
stahk angina pectoris. Am J Cardiol 1990:66: 164-7. 
I:. Dargie H.I. Ray SG. The efl'ects of angiotensin-converting enzyme inhi-
bition 011 wronary hlood flow and infarct size limitation. J Hum Hyper-
tens 19H1JJhupplll:I-IOI-6. 
Il Pfefl'er MA. Lamas GA. Vaughn DE. et al. Effect of captopril on 
progressive ventricular dilatation after anterior myocardial infarction. 
N Engl J Med 1988:3 19:HO-6. 
14. Engelmeier RS. O'Connell JB. Walsh R. Rad N. Scanlon PJ. Gunnar RM. 
Improvement in symptoms and exercise tolerance by metoprolol in 
patients with dilated cardiomyopathy: a double-blind. randomized. pla-
cebo-controlled trial. Circulation 1985:7::536-46. 
15. Gilhert EM. Anderson JL. Deitchman D. et al. Long-term /3-blocker 
vasodilator therapy improves cardiac function in idiopathic dilated car-
diomyopathy: a double-hlind. randomized study of bucindolol versus 
placeho. Am J Med 1990:88:::3-9. 
16. Woodley SL. Gilbert EM. Anderson JL. et al. Differing effect of chronic 
f3-blockade with bucindolol cardiac function in patients with idiopathic vs. 
ischemic cardiomyopathy (abstl'). Circulation 1989:80(supplll):lI-IIH. 
17. Chadd a K. Goldstein S. Byington R. Curb 10. Effect of propranolol after 
acute myocardial infarction in patients with congestive heart failure. 
Circulation 19Xo:7l503-10. 
IX. Multicenter Diltiazem Post-Infarction Research Group. The effect of 
diltiazem on mortality and reinfarction after myocardial infarction. 
N Engl J Med 19HHJ 19:3X5-9:. 
19. Packer M. Calcium channel blockers in chronic heart failure: the risks of 
"physiologically rational" therapy. Circulation 1990:82:2254-7. 
:0. Hall D. Zeitler H. Schwarz A. Rudolph w. In congestive heart failure. 
aspirin counteracts the beneficial hemodynamic effects of enalapril (ab-
strl. Circulation 1990:8:(suppl 1111:111-317. 
:1. Kennedy JW. Kaiser Gc. Fisher LD. et al. Clinical and angiographic 
predictors of operative mortality from the collaborative study in coronary 
artery surgery (CASSI. Circulation 19HI:63:793-80~. 
::. Alderman EL. Fisher LD. Litwin P. et al. Results of coronary artery 
surgery in patient> with poor left ventricular function (CASS). Circulation 
19R3 :68:785-95. 
